2016
DOI: 10.1556/650.2016.30336
|View full text |Cite
|
Sign up to set email alerts
|

Intestinalis zsírsavkötő fehérje: az enterocytakárosodás markere akut és krónikus gasztroenterológiai kórképekben

Abstract: DebrecenAz intestinalis zsírsavkötő fehérje a zsírsavkötő fehérjék családjába tartozó, a vékony-és vastagbél enterocytáinak citoszoljában termelődő, kis molekulasúlyú fehérje. Az enterocytasejtek membránintegritásának megbomlását köve-tően megjelenik a szisztémás keringésben, és a vesék glomerularis szűrőjén keresztül kiválasztódik a vizeletbe. A szerzők akut és krónikus enterocytakárosodással járó gastrointestinalis kórképekben az intestinalis zsírsavkötő fehérje biomarkerként való használatával kapcsolatos v… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 39 publications
0
1
0
Order By: Relevance
“…However, reports on the differences in the fecal metabolites profile between the RD infants and healthy (H) infants are limited. Among many fecal metabolites, the changes in fecal amino acids (AAs) and fatty acids (FAs) contributed to reveal the relationship between intestinal diseases and fecal metabolites profile (7,8). On the one hand, fecal proteins profile has been reported to be affected by intestinal diseases, and the significant differences in composition of fecal proteins have been found in patients suffering from intestinal disease, such as a significant increase of calprotectin and lactoferrin in feces of patients with inflammatory bowel disease (9,10).…”
Section: Introductionmentioning
confidence: 99%
“…However, reports on the differences in the fecal metabolites profile between the RD infants and healthy (H) infants are limited. Among many fecal metabolites, the changes in fecal amino acids (AAs) and fatty acids (FAs) contributed to reveal the relationship between intestinal diseases and fecal metabolites profile (7,8). On the one hand, fecal proteins profile has been reported to be affected by intestinal diseases, and the significant differences in composition of fecal proteins have been found in patients suffering from intestinal disease, such as a significant increase of calprotectin and lactoferrin in feces of patients with inflammatory bowel disease (9,10).…”
Section: Introductionmentioning
confidence: 99%